Potential Benefits of Obesity Drug in Tackling Type 2 Diabetes
August 21, 2024
August 21, 2024
LIVERPOOL, England, Aug. 21 (TNSres) -- The University of Liverpool issued the following news release:
Researchers at the University of Liverpool have found that the weight loss drug, Tirzepatide is associated with significantly reduced risk of developing type 2 diabetes (T2D).
Obesity is a major worldwide health concern. Current global estimates of the number of adults living with obesity is at 650 million, with a further 340 million children and adolescents. Overweigh . . .
Researchers at the University of Liverpool have found that the weight loss drug, Tirzepatide is associated with significantly reduced risk of developing type 2 diabetes (T2D).
Obesity is a major worldwide health concern. Current global estimates of the number of adults living with obesity is at 650 million, with a further 340 million children and adolescents. Overweigh . . .